

13 August 2019
ASX Code: MXC

MGC Pharma Achieves 100 Patient Milestone in Australia & onboards new medical cannabis provider, Tetra Health

ASX RELEASE

MGC Pharmaceuticals Ltd (ASX: MXC, ‘MGC Pharma’ or ‘the Company’), a European based ‘Seed to Pharmacy’ bio-pharma company focused on developing and commercialising cannabinoid derived medicines, is pleased to announce positive developments on its Pharmaceutical operations in the Australian market.

Key Highlights:

- 100 patients in Australia already prescribed or being processed ahead of receiving a prescription for MGC Pharma’s pharmaceutical products, CannEpi™ or MXP100 (100mg/mL cannabidiol)
- Bulk shipment of CannEpi™ and MXP100 en route to Australia to be prescribed to patients under the Special Access Scheme
- New patient registrations being collected ahead of CannEpi™ and MXP100 shipment, through distribution arrangements in Australia with Health House and Cannvalate
- Recent addition of a new clinic and quick uptake of patients is testament to the quality and cost competitiveness of MGC Pharma’s cannabinoid derived pharmaceutical products
- Tetra Pty Ltd (‘Tetra Health’), an organisation that assists medical professionals and patients to obtain safe access to medicinal cannabis products, have added MGC Pharma products to their product range
- Tetra Health will work directly with MGC Pharma’s pharmaceutical products wholesaler and distributor, Health House International
- Planning underway to import additional MGC Pharma pharmaceutical products during August, broadening the range of products available and increasing potential patient numbers

Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “To have reached 100 patients now prescribed or being processed to receive our products in a relatively short amount of time is a major milestone for the Company. We anticipate our number of patients to increase as we broaden our product range available for prescription, and with products in Australia available for immediate supply. Our cannabinoid based pharmaceutical products are of consistent high-quality at an affordable price, and we believe that this is a key differentiator for the Company and will encourage prescriptions.

“The agreement with Tetra Health serves to further advance the commercialisation of our cannabinoid derived pharmaceutical products in Australia by connecting greater numbers of patients with products through Tetra’s established network of prescribing physicians and partnering clinics.”

Ian Mutton, Chairman of Tetra Health, commented: “We are delighted to add MGC Pharma’s cannabinoid medicines to our diverse product offering. Matched with our own 500%+ increase in prescribed patient growth over the last month, this relationship allows us to add much needed medications to our product line to service our diverse patient cohort across Australia and grow with another Australian based supplier of cannabinoid based therapeutics.”

Further Information

Reaching 100 patients prescribed or being processed for prescription of MGC Pharmaceuticals cannabinoid derived pharmaceutical products is a material achievement for the Company. It represents our increasing position in the medical cannabis sector in Australia, whilst also working towards becoming a world-leading bio-pharma company through our international distribution agreements and increasing production from our European manufacturing facility in Slovenia.

As outlined in the ASX announcements dated 25 January 2018, 29 March 2018 and subsequent Company announcements referencing CannEpiTM, the Company set a key milestone for the business in the Australian market based on achieving its first 100 patients that will now be delivered following the arrival of this new shipment in August. The Company has been working diligently with its distributors in Australia to onboard clinics providing us with access to additional eligible patients under the Special Access Scheme with this new product shipment shortly arriving in Australia.

Tetra Health

MGC Pharma has facilitated a supply deal of its pharmaceutical products through its wholesaler and distributor, Health House International, with Tetra Health, an Australian based company that facilitates safe and responsible access to medicinal cannabis treatment and medicines. Tetra Health aims to streamline patient access through the education of healthcare providers on how to prescribe medicinal cannabis and manage treatment outcomes, providing ongoing support and patient monitoring using specialist nurses. Tetra Health, through its established network of partners, has managed over 30,000 global patients.

Under the terms of the agreement, Tetra Health shall purchase MGC Pharma's products wholesale from the Company's distributor Health House International to then be distributed to Tetra Health's network of pharmacies, prescribing physicians and partnered clinics. There are no specified minimum contract amounts or volumes under this agreement.

--Ends--

For further information, please contact:

UK IR/Media Advisors

Gaby Jenner/ Catherine Leftley

St Brides Partners Ltd

+44 (0) 207 236 1177

gaby@stbridespartners.co.uk

catherine@stbridespartners.co.uk

MGC Pharmaceuticals Ltd

Brett Mitchell

Executive Chairman

+61 8 6382 3390

info@mgcpharma.com.au

About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is an EU-based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality cannabinoids-based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels    